Top Story Today
Novo's Obesity Drug Was Built to Match Lilly. It Got Knocked Out Instead.
Novo Nordisk's CagriSema didn't even need to beat Lilly's tirzepatide in the REDEFINE 4 trial. It just needed to prove it was roughly equivalent. It couldn't. After 84 weeks, CagriSema delivered 23% weight loss versus tirzepatide's 25.5%, and the statistical bar for non-inferiority wasn't met. Shares cratered more than 16% in a single session, extending a prolonged decline from Novo's peak valuation. Goldman Sachs slashed CagriSema's peak sales estimate from approximately $11.8 billion to $5.2 billion, and one analyst said it's "challenging to pinpoint a reason why a patient would be prescribed CagriSema over Zepbound."
Why it matters: This wasn't just a clinical miss; it was a competitive coronation. Lilly's tirzepatide franchise already generates $36.5 billion in annual sales, and this head-to-head validates its dominance while forcing Novo to bet its future on higher doses, oral formulations, and M&A diversification worth tens of billions.
Read more →Deals and M&A
AbbVie Drops $10.9 Billion on a Company That Didn't Exist Four Years Ago
AbbVie is paying $10.9 billion in cash for Apogee Therapeutics, a four-year-old biotech whose lead eczema drug hasn't even started Phase 3. The hook: patients on zumilokibart may need just two to four injections per year, versus Dupixent's 26. That convenience edge, combined with strong Phase 2 data (65.9% skin clearance), convinced AbbVie to pay a 49% premium as it builds its post-Humira immunology dynasty.
Read more →Pfizer Hammered Out a 12-Program Oncology Deal with Innovent in Five Months
Pfizer and China's Innovent Biologics closed a $10.5 billion collaboration spanning 12 cancer programs at startup speed. Only $650 million lands upfront; the rest rides on milestones and royalties. Pfizer is treating the deal like a venture portfolio: twelve shots on goal across ADCs and multispecific antibodies, with milestone-based revenue arriving over time as programs progress.
Read more →Big Pharma's $106 Billion Shopping Spree Could Smash the All-Time Record
Biopharma M&A has hit $106 billion across 201 deals in 2026, on pace to blow past $250 billion and eclipse even the legendary 2019 peak. The driver: over $230 billion in patent revenue expires by 2030. The sweet spot is $1 billion to $5 billion bolt-on acquisitions, with obesity, oncology, and immunology accounting for the lion's share of activity.
Read more →Lilly Pays $10 Million for a Swedish Alzheimer's Drug That Could Be Worth 100x More
Eli Lilly licensed ACD680, an oral pill designed to slow amyloid production in the brain, from 11-person Swedish biotech AlzeCure for $10 million upfront and over $990 million in milestones. If Lilly's existing drug Kisunla is a mop for clearing plaques, this pill is the faucet handle to stop new ones from forming. AlzeCure's stock spiked 300%.
Read more →SK Biopharma and Insilico Ink $2.5 Billion AI Neuroimmune Pact (for $18 Million Down)
SK Biopharmaceuticals signed one of the largest AI drug discovery deals ever with Insilico Medicine, targeting neuroimmune diseases. The headline number is $2.5 billion, but only $18 million is guaranteed upfront: a 140:1 ratio between promise and payment. SK gets full ownership of any candidates, while Insilico earns milestones and single-digit royalties.
Read more →Clinical and Regulatory
An LSD Pill Just Posted the Best Depression Data Anyone Has Ever Seen
A single dose of Definium's LSD-derived pill DT120 beat placebo by 8.1 points on a standard depression scale at Week 6, roughly double what Spravato achieved in some pivotal trials. By Week 1, the gap was a staggering 14.2 points. Effects lasted through three months, no therapy sessions required. The stock surged as much as 63%. A second pivotal trial is already enrolling.
Read more →The FDA Just Got a Live Feed Into Two Cancer Trials
The FDA launched its real-time clinical trials initiative with AstraZeneca and Amgen oncology studies, replacing the decades-old model of periodic data dumps with near-continuous safety and efficacy signals. The agency's chief AI officer estimates this could cut trial timelines by 20 to 40%. Both pilots are in aggressive cancers where faster decisions could meaningfully change patient outcomes.
Read more →Did a Presidential Phone Call Reverse the FDA's Decision on Moderna?
The FDA refused to review Moderna's mRNA flu vaccine application, then reversed course roughly a week later. In between, Politico reports, President Trump summoned the FDA commissioner to the White House. The agency ultimately found a "very reasonable" path forward, but the timeline raises uncomfortable questions about political influence over regulatory decisions.
Read more →Funding and Startups
A French Biotech Raised $165 Million Without Discovering a Single Molecule
Bionyra Pharma launched with the largest French biotech Series A on record, raising $165 million to license (not discover) three inflammation drugs from Chinese and U.S. partners. Two programs are already in or entering Phase 1. The playbook: skip the riskiest years of early research, buy de-risked molecules, and build a portfolio that big pharma will want to acquire.
Read more →